Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report)'s share price fell 1.6% during mid-day trading on Wednesday . The stock traded as low as $13.32 and last traded at $13.35. 28,088 shares changed hands during trading, a decline of 30% from the average session volume of 39,985 shares. The stock had previously closed at $13.57.
Wall Street Analyst Weigh In
Separately, HC Wainwright boosted their target price on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the company a "buy" rating in a report on Friday, August 23rd.
View Our Latest Stock Report on GLSI
Greenwich LifeSciences Stock Up 1.8 %
The business's 50-day simple moving average is $14.00 and its two-hundred day simple moving average is $14.46. The firm has a market capitalization of $178.71 million, a price-to-earnings ratio of -16.90 and a beta of 1.62.
Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.20). Sell-side analysts anticipate that Greenwich LifeSciences, Inc. will post -0.81 earnings per share for the current year.
Institutional Trading of Greenwich LifeSciences
Institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers acquired a new stake in shares of Greenwich LifeSciences in the 2nd quarter valued at about $117,000. Bank of New York Mellon Corp purchased a new position in Greenwich LifeSciences during the 2nd quarter worth $264,000. Finally, Vanguard Group Inc. increased its holdings in shares of Greenwich LifeSciences by 0.6% in the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company's stock valued at $4,449,000 after purchasing an additional 1,420 shares during the period. 4.16% of the stock is currently owned by hedge funds and other institutional investors.
Greenwich LifeSciences Company Profile
(
Get Free Report)
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Read More
Before you consider Greenwich LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.
While Greenwich LifeSciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
